New Formulations for Approved mRNA Vaccines
Challenge  9934335|
https://innocentive.wazoku.com/?utm_campaign=InnoCentive%20Bulletin&utm_medium=email&_hsmi=121378074&_hsenc=p2ANqtz-_Z-MznYFDyjnSZ6EX_cIUB9p8GGCBE0FP-rnzeqdrboxIFQg8DYSq5RBlv1_HMN9K5T44w66RBJyo5XDph5p24GcScyg&utm_content=121378074&utm_source=hs_email#/challenge/66db2c8ac4d449cb94a7acb84dae20e5  

As we enter the second year of the COVID-19 pandemic, vaccinations provide hope that the world will soon be back to normal. Vaccines that are based upon messenger RNA (mRNA) technology require two shots spaced several weeks apart for optimal efficacy. Therefore, the Seeker is interested in a new vaccine formulation that confers the same level of protection with a single injection.
 This Theoretical Challenge requires only a written proposal.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on May 28, 2021

Traditional vaccines work by training the immune system to recognize and fight pathogens—but mRNA vaccines work by instructing host cells to produce and display proteins that trigger antibody responses. This reduces the risk of post-vaccination infection, but mRNA vaccines often require multiple doses and must be stored at extremely low temperatures. Therefore, Debiopharm is interested in a new vaccine formulation that confers the same level of protection with a single injection.